Equities

Thalys Medical Technology Group Corp

603716:SHH

Thalys Medical Technology Group Corp

Actions
Health CareMedical Equipment and Services
  • Price (CNY)5.79
  • Today's Change-2.42 / -29.48%
  • Shares traded5.92m
  • 1 Year change-50.30%
  • Beta0.9427
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Thalys Medical Technology Group Corp, formerly Thalys Medical Technology Inc, is a China-based company principally engaged in the provision of intensified distribution business and simple sales business and the research, design, manufacture and distribution of independent in vitro diagnostic products. Its product type includes purchased reagents and consumables, self-produced reagents and consumables, as well as purchased equipment. The Company mainly operates its business in domestic markets, with Hubei, Hunan, Jiangsu, Henan and Shanghai province as its major markets.

  • Revenue in CNY (TTM)1.90bn
  • Net income in CNY-210.78m
  • Incorporated2004
  • Employees1.41k
  • Location
    Thalys Medical Technology Group CorpNo.1310 Jinshan AvenueDongxi Lake DistrictWUHAN 430040ChinaCHN
  • Phone+86 2 783386378
  • Fax+86 2 783084202
  • Websitehttps://www.thalys.net.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Rightongene Biotechnlgy Co Ltd249.02m-5.17m1.21bn501.00--1.28--4.84-0.0877-0.08774.4316.870.23841.201.32497,050.10-1.374.16-1.464.4972.9870.45-5.7511.6211.12--0.0255.90-39.142.84-80.41-11.4619.65--
AVE Science & Technology Co Ltd202.67m22.56m1.22bn492.0054.172.45--6.030.33180.33182.987.350.36831.9330.00411,925.304.107.214.468.1856.7358.9311.1315.485.51--0.0022.461.795.8819.81-4.62-23.68--
Jiangsu Nanfang Medical Co Ltd584.85m-167.99m1.29bn858.00--2.83--2.21-0.5812-0.58122.021.580.42941.863.49681,641.10-12.31-1.09-28.91-2.005.6420.14-28.66-1.910.3748-9.580.5314--10.034.57-906.35---3.18--
Suzhou Iron Technology Co Ltd323.32m-43.37m1.30bn680.00--1.73--4.01-0.5716-0.57164.249.720.23431.931.18475,466.10-3.407.11-5.4810.5646.2456.00-14.5219.171.23-4.900.257125.00-23.848.73-71.17-10.4036.50--
CareRay Digital Medical Technology CoLtd287.84m24.70m1.32bn252.0054.181.55--4.590.27690.27693.229.690.30621.603.921,142,221.002.626.652.857.3742.7641.178.5515.646.76--0.022427.6133.815.17374.05-20.7477.38--
Touchstone International Medi Sci Co Ltd274.03m56.95m1.53bn243.0025.732.67--5.570.7310.7313.517.050.43523.1618.941,127,699.009.0510.0910.0610.8255.9657.5920.7820.174.76--0.002824.669.3116.349.5315.39-2.39--
Thalys Medical Technology Group Corp1.90bn-210.78m1.65bn1.41k--1.55--0.8715-1.36-1.3611.685.310.55084.161.221,349,051.00-6.04-0.8933-11.27-1.6218.5122.12-10.97-1.491.43-0.96660.4974---13.108.77-2.69---19.20--
Shanghai Rendu Biotechnology Co Ltd177.96m21.27m1.67bn358.0078.731.81--9.410.53180.53184.4523.180.17341.292.41497,088.502.076.262.227.1779.8774.3611.9514.5412.02--0.00527.96-45.8918.85-64.60--23.48--
Guangzhou LBP Medicine Scnc&Tech Co Ltd495.46m32.09m1.89bn907.0059.141.48--3.810.34140.34145.2113.620.35942.011.98546,263.801.845.101.925.5566.9275.155.1212.977.74--0.010124.42-1.9910.18-6.18-8.21-2.98--
Guangzhou Jet Bio-Filtration Co Ltd524.26m70.98m2.04bn1.09k25.921.74--3.880.55980.55984.138.320.32463.304.08480,536.104.419.354.6810.3937.7136.7613.6017.897.825.330.233329.64-24.0617.42-60.34-8.0247.32--
Allgens Medical Technology Co Ltd191.19m5.11m2.28bn202.00483.351.61--11.940.03480.03481.4510.490.12511.322.81946,490.300.02327.620.02418.3073.8783.600.185539.0524.27--0.03335.25-7.6812.86-43.0410.46-26.12--
Data as of Sep 13 2024. Currency figures normalised to Thalys Medical Technology Group Corp's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.51%Per cent of shares held by top holders
HolderShares% Held
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2024373.90k0.39%
China Asset Management Co., Ltd.as of 30 Jun 202480.90k0.08%
Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 202437.80k0.04%
Goldstate Capital Fund Management Co., Ltd.as of 30 Jun 20240.000.00%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20240.000.00%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 20240.000.00%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 20240.000.00%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.